Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.
- Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currency
- Women’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility products
- Biosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4
- Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in China
- Q4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023
- On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last year
- At $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Richtech’s mission is to transform the service industry through collaborative robotic solutions: President
Richtech Robotics Inc. (NASDAQ: RR) is a leading provider of robotic solutions, developing, manufacturing, and deploying novel products needed for automation in the service industry. The company's solutions include delivery,
What to expect when Darden Restaurants reports Q1 results
Darden Restaurants, Inc. (NYSE: DRI) is scheduled to release its first-quarter report on September 19, with analysts forecasting a year-over-year increase in sales and profit. The market will be keeping a
Oracle (ORCL) sees continued strong revenue growth in FY25
Oracle Corporation (NYSE: ORCL) started the new fiscal year on a high note with stronger-than-expected first-quarter results, driving the stock higher soon after the announcement. The tech giant’s earnings and
